Questcor Pharmaceuticals (FRA:QPH) EPS (Basic) : €4.41 (TTM As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Questcor Pharmaceuticals EPS (Basic)?

Questcor Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Jun. 2014 was €1.19. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2014 was €4.41.

Questcor Pharmaceuticals's EPS (Diluted) for the three months ended in Jun. 2014 was €1.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2014 was €4.19.

Questcor Pharmaceuticals's EPS without NRI for the three months ended in Jun. 2014 was €1.13. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2014 was 4.19.

During the past 12 months, Questcor Pharmaceuticals's average EPS without NRIGrowth Rate was 54.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 106.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 95.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Questcor Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 106.60% per year. The lowest was -52.50% per year. And the median was 5.00% per year.

Questcor Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Questcor Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Questcor Pharmaceuticals EPS (Basic) Chart

Questcor Pharmaceuticals Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

EPS (Basic)

Get a 7-Day Free Trial

0.28

0.42

0.97

2.50

3.64

Questcor Pharmaceuticals Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
EPS (Basic)	Get a 7-Day Free Trial															0.89	1.20	1.11	0.91	1.19

Questcor Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Questcor Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2013 is calculated as

Basic EPS (A: Dec. 2013 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(213.605	-	0)	/	58.616
	=	3.64

Questcor Pharmaceuticals's Basic EPS for the quarter that ended in Jun. 2014 is calculated as

Basic EPS (Q: Jun. 2014 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(70.977	-	0)	/	59.686
	=	1.19

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.41

Questcor Pharmaceuticals (FRA:QPH) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Questcor Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Questcor Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Questcor Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Questcor Pharmaceuticals Inc (FRA:QPH) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.questcor.com

Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.

Questcor Pharmaceuticals Headlines

No Headlines